In a mouse model, to decrease immunosuppressive MDSCs infiltration in tumors, an aptamer against C5a anaphylatoxin chemotactic receptor (C5aR) was combined with PD-1 blockade, showing synergy in inhibiting KRAS-driven lung cancer [160]. Here, PDCD1 is linked to lung carcinoma.